ClinicalTrials.gg
RecruitingNCT05086432SpECC-ILDUpdated Oct 7, 2026

Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD

An interventional study of Sputum-guided management and Standard of Care in ILD, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by McMaster University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Chronic Cough with a site in Canada — 7 open to participants now, 8 under way, none of them phase 3. Chronic Cough · Canada.

Planned enrollment
10th of 18
120 · median 122
Started
2025
with 2 others
No phase
2 of 22
2 open now
Registered
12th of 22
by date
Lead sponsor
7 of 22
McMaster University

Among the 22 studies in Chronic Cough with a site in Canada, this one is the 10th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 with no phase, and was the 12th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

7 of the 22 studies in Chronic Cough with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Chronic Cough with a site in Canada, or all of them as a file.
02

Study summary

In Interstitial Lung Disease (ILD) there is thickening of lung tissue, which makes it difficult for patients to breathe and get enough oxygen into their bodies. In addition to shortness of breath, daily cough is very common, with 4 out of 5 patients experiencing this symptom. Cough in particular has a major impact on the ability to exercise, be active, and to simply enjoy life.

There are many reasons for cough in ILD, and very often there are multiple overlapping causes. It is hard to improve cough in these patients, with available medicines providing limited relief. One explanation for this gap is an incomplete understanding of cough in ILD. To improve patients' cough there is a need to better understand its cause. In other lung diseases, such as asthma, doctors and scientists have used phlegm tests to measure inflammation in the lung, which helps them choose the right medicine for the right patient. This has not been done for ILD, even though it has recently been found that many patients with ILD and everyday cough have abnormal phlegm tests. Using this strategy in ILD could improve patients' cough and quality of life, and possibly even slow progression of the disease.

Read the detailed description

SpECC-ILD is an open-label, randomized controlled trial assessing the efficacy of sputum-guided management (using sputum cytometry) compared to standard care over 16 weeks in patients with chronic cough and ILD.

A total of 80 participants will be enrolled and randomized in a 1:1 ratio to either sputum guided therapy or standard of care for a total of 16 weeks. Participants randomized to the intervention arm will receive open-label sputum-guided management of airway inflammation identified during screening. Participants in this arm will receive standard of care treatment as determined by their ILD specialist who will be blinded to the results of the sputum analysis.

03

Conditions studied

  • ILD

Browse trials for

Keywords

  • ILD
  • Sputum
  • Chronic cough
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consistent with ICH-GCP and local laws, signed prior to any study procedures being performed
  • Age >18 years
  • A clinical diagnosis of ILD with accepted specific diagnoses including:
  • Idiopathic pulmonary fibrosis (IPF)
  • Chronic pneumonitis associated ILD (CHP-ILD)
  • Connective tissue disease associated ILD (CTD-ILD)
  • Pneumoconiosis
  • Daily Cough for at least 8 weeks
  • Able to produce an adequate sample with sputum induction

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of systemic sclerosis associated ILD (SSc-ILD) or sarcoidosis
  • Cause of cough attributed to a known etiology (ex. ACE-inhibitor, uncontrolled gastroesophageal reflux or upper airway cough syndrome, acute viral illness)
  • Current use of inhaled
  • Current use of systemic corticosteroids (prednisone equivalent > 20mg/day)
  • Current use of chronic antibiotics
  • Airflow obstruction (ie. pre-bronchodilator /FVC ratio \< 0.7)
  • History of physician-diagnosed asthma
  • History of emphysema
  • A history of cholestatic jaundice or hepatic dysfunction associated with prior use of azithromycin
  • Moderate to severe hepatic dysfunction with a score >10
  • Known allergy or to inhaled corticosteroids or macrolide antibiotics
  • -interval (QTc) on screening (ECG) of > 450ms
  • An established history of untreated atypical mycobacterial infection
  • A history of hearing impairment, tinnitus, or vertigo
  • Medication use likely to suppress cough (ex: morphine, gabapentin, amitriptyline)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Sputum-guided management

    During Weeks 0 to 16, participants randomized to the intervention arm will receive open-label sputum-guided management of airway inflammation (Table 1 in protocol) identified during screening (Figure 2 in protocol). Airway eosinophilia will be treated with regular inhaled corticosteroids based on the severity of eosinophilic inflammation. In participants with airway neutrophilia, as per the standard of care, sputum culture and sensitivity will be sent, and pathogenic organisms treated. Those participants with airway neutrophilia with negative cultures will be treated with thrice weekly Azithromycin (250mg). Combined eosinophilia and neutrophilia will receive treatment with both ICS and Azithromycin as per Table 2 in protocol.

    Other: Sputum-guided management

  • Active comparator
    Standard of Care

    Participants in this arm will receive standard of care treatment as determined by their ILD specialist who will be blinded to the results of the sputum analysis.

    Other: Standard of Care

Interventions

  • OtherSputum-guided management

    As previously described.

  • OtherStandard of Care

    As previously described.

06

What researchers measure

Primary outcomes

  1. Change in hourly cough frequency

    The difference in hourly cough frequency over a 24-hour period between baseline and end of study.

    Time frame: 16 weeks

Secondary outcomes

  1. Change in FEV1

    The difference in forced expiratory volume in 1 second (as obtained by spirometry) between baseline and end of study

    Time frame: 16 weeks

  2. Change in FVC

    The difference in forced vital capacity (as obtained by spirometry) between baseline and end of study

    Time frame: 16 weeks

  3. Change in Leicester Cough Questionnaire

    The difference in LCQ between baseline and end of study

    Time frame: 16 weeks

  4. Change in King's Brief ILD Questionnaire

    The difference in KB-ILD between baseline and end of study

    Time frame: 16 weeks

  5. Change in sputum total cell count

    The difference in sputum total cell count between baseline and end of study

    Time frame: 16 weeks

  6. Change in sputum neutrophils

    The difference in sputum neutrophil percent between baseline and end of study

    Time frame: 16 weeks

  7. Change in sputum eosinophils

    The difference in sputum eosinophil percent between baseline and end of study

    Time frame: 16 weeks

  8. Adverse events

    Adverse events reported by participants

    Time frame: 16 weeks

  9. Serious adverse events

    Serious adverse events reported by participants

    Time frame: 16 weeks

  10. Completion rates for Bi-weekly LCQ

    Rates of completion for bi-weekly LCQ

    Time frame: 16 weeks

  11. Study medication adherence rate

    Rates of adherence to study medications

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 21 interventional studies with no phase under Chronic Cough, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 48. This study's planned 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 20, 2021
StartActual
May 22, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05086432
Collaborators
St. Joseph's Healthcare Hamilton, Vitalograph
Responsible party
Sponsor
First posted
Oct 20, 2021
Start date
May 22, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Ciaran Scallan, MB
Contact
scallc@mcmaster.ca
9055221155 ext. 34330
Terence Ho, MB, MSc
Contact
hot4@mcmaster.ca
9055221155 ext. 32995

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion